More information about Amicus Therapeutics and its career opportunities may be found at www.amicusrx.com. Amicus is pleased to submit its new Japanese drug application for its oral precision medicines to combat Fabry disease in Japan. Japan’s a key part of its patient-focused vision in providing migalastat to amenable Fabry patients all over the world – as quickly as possible.
Amicus congratulated Chip Baird for receiving the NJ Tech Council Caren Franzini Hall of Fame Award. Baird’s multiple career achievements have thus elevated him to such recognition among his peers. Team Amicus Therapeutics (:Small Biotech Seems To Have The ‘Big Mo’) also spent three days volunteering through Habitat for Humanity’s Monmouth County – HFHMC – division, serving North East and Western Monmouth County within New Jersey. HFHMC sides with communities to develop decent, affordable housing anyone can live and raise a family.
Amicus Therapeutics was also pleased to share positive data from its newest Pompe Phase 1/2 clinical study, which showed a significant step forward in its mission to develop improved treatment options for those living with Pompe disease. Listen to its live conference calls at 8:30am ET to find out more, or access any replay and slide presentations on the website. Amicus likewise shared its first-quarter 2017 financial results and discussed its 2017 key strategic priorities, including an international launching of its precision medicine to combat Fabry disease, advancements of its Pompe disease with Epidermolysis Bullosa clinical programs, and additional corporate updates. The Webcast and replay were available online.